-
Hengrui's Application for New Class 1.1 Drug Hetrombopag Ethanolamine Tablets was Accepted by CDE
PharmaSources/Dopine
June 19, 2020
On June 18, the marketing application of Hengrui's new class 1.1 drug Hetrombopag ethanolamine tablets was accepted by CDE.
-
Eurofins CDMO Expands Drug Product Capabilities in Canada
contractpharma
November 06, 2020
Eurofins CDMO has expanded its existing drug product operation capabilities with the early 2020 completion of its new drug product development and cGMP manufacturing facility, located in Mississauga, Canada.
-
FDA new drug approvals down 16 percent in 2019, impacting outsourcing
europeanpharmaceuticalreview
May 14, 2020
A new report has found that in 2019 the FDA approved 119 new drugs and biologics, but that this is down from 137 in 2018, impacting contract manufacturing organisations.
-
Harvest in 2019 year-end with the Marketing of Multiple Generic Drugs
PharmaSources/Caicai
January 07, 2020
The NMPA is also “sprinting” as the year is coming to an end.
-
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
pharmaceutical-business-review
December 11, 2019
Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets ...
-
Shanghai Green Valley’s Class 1 New Drug for Alzheimer’s Disease Conditionally Approved for Marketing and Already Having the Registration Approval!
PharmaSources/Caicai
November 14, 2019
The National Medical Products Administration of China (NMPA) released on its website yesterday (Nov. 2, 2019) some big news that shocks the industry.
-
UF researchers focus on new drug candidate Apratoxin S4 to treat vision loss
pharmaceutical-technology
August 12, 2019
Researchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug candidate Apratoxin S4 as a new method to prevent or treat vision loss.
-
Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution
prnasia
August 06, 2019
3SBio Inc. (01530.HK), a leading biopharmaceutical company in the PRC, announces today that an application for the production of new drug has been submitted to the National Medical Products Administration for ...
-
New Drug for Diabetes-Induced Vision Loss TGA-Approved for Australian Patients
prnasia
August 06, 2019
Australian patients with diabetes-induced eye disease can now access a new treatment option that provides consistent and continuous treatment with long-lasting effect.
-
FDA approves new drug to treat influenza
fda
November 09, 2018
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older